Tirzepatide Price vs. Wegovy: Which Weight Loss Drug is Cheaper?

The Core Cost Difference

When comparing tirzepatide price to Wegovy, the numbers are close enough to surprise most patients. Mounjaro (tirzepatide, approved for type 2 diabetes) carries a list price of roughly $1,000 to $1,100 per month without insurance, while Zepbound (tirzepatide approved specifically for obesity) launched at approximately $1,059 per month. Wegovy (semaglutide 2.4 mg) lists at about $1,350 per month. On sticker price alone, tirzepatide is the cheaper option by $250 to $350 monthly, which adds up to $3,000 or more per year.

These are list prices, not what most patients actually pay. Insurance coverage, manufacturer coupons, and compounding pharmacies can shift the real-world cost dramatically in either direction. Understanding each layer is essential before assuming one drug will be more affordable for you personally.

Insurance Coverage: Where the Real Math Happens

Wegovy has a modest edge in obesity-specific insurance coverage because semaglutide (Ozempic) has been on the market longer and Novo Nordisk invested heavily in payer negotiations. Some commercial plans cover Wegovy for patients with a BMI of 30 or above, or 27 with a qualifying comorbidity. Zepbound received FDA approval for obesity in November 2023, and coverage is expanding but still lags Wegovy on many formularies as of 2025.

Patients using Mounjaro for type 2 diabetes often find better reimbursement than those seeking either drug for weight loss alone. Medicare Part D covers neither Wegovy nor Zepbound for obesity under current federal law, making out-of-pocket cost the only option for most Medicare beneficiaries regardless of which drug they choose.

Manufacturer Savings Programs

Eli Lilly offers a savings card for Zepbound that can bring the monthly tirzepatide price down to as low as $550 for commercially insured patients, and a separate program targeting uninsured patients. Novo Nordisk runs a similar Wegovy savings program capping costs at roughly $650 per month for eligible commercially insured individuals. For uninsured patients, Lilly has also offered vials of tirzepatide through its direct-to-consumer platform at prices starting around $399 per month for lower doses, a significant departure from the traditional pharmacy model.

These programs come with income limits, insurance status requirements, and dose restrictions that change frequently. Always verify current eligibility on the manufacturer's official website rather than relying on figures from articles, including this one.

Compounding Pharmacies: The Low-Cost Alternative

During the FDA shortage period for semaglutide and tirzepatide, compounding pharmacies legally produced copies of both drugs. Compounded semaglutide and compounded tirzepatide were widely available at $150 to $400 per month, representing enormous savings versus brand-name options. The FDA declared the tirzepatide shortage resolved in late 2024, triggering restrictions on compounding, and the semaglutide shortage resolution followed.

As of 2025, compounded versions are subject to tighter restrictions. FDA-registered 503B outsourcing facilities may still produce certain compounded formulations under specific conditions, but 503A retail compounding pharmacies face much stricter limits. Patients should be cautious: compounded GLP-1 medications lack FDA approval for safety and efficacy, and quality can vary significantly between pharmacies.

Which Drug Delivers More Value Per Dollar?

Clinical trial data favors tirzepatide on weight loss outcomes. The SURMOUNT-1 trial showed average body weight reductions of up to 22.5% at the highest dose of tirzepatide, compared to approximately 15% in the STEP 1 trial for semaglutide 2.4 mg. If tirzepatide produces greater weight loss at a similar or lower tirzepatide price, the cost-per-kilogram-lost calculation shifts meaningfully in its favor.

That said, individual response varies considerably. Some patients lose significantly more weight on semaglutide, and tolerability differs. Side effect profiles are similar — primarily nausea, vomiting, and diarrhea — but a drug that works better for a specific individual will always deliver better value regardless of its list price.

• Zepbound list price: approximately $1,059 per month
• Wegovy list price: approximately $1,350 per month
• With savings cards (commercially insured): $550 vs. $650 per month
• Medicare coverage for obesity: neither drug is currently covered
• Average weight loss advantage: tirzepatide leads by roughly 5 to 8 percentage points in head-to-head trial comparisons

Bottom Line

Tirzepatide is generally the cheaper option at list price and through most savings programs, while also outperforming semaglutide in average weight loss in clinical trials. Wegovy retains an advantage in insurance formulary acceptance at some payers, which could make it the net cheaper option for specific plan holders. The only way to know your actual cost is to run both drugs through your specific insurance plan, check current manufacturer savings eligibility, and discuss clinical suitability with your prescriber. Price matters, but the drug that produces better results for your metabolism is the one that delivers real value over time.